KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Diluted Average) (2020 - 2025)

Aquestive Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $106.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $106.9 million for Q4 2025, up 23.29% from a year ago — trailing twelve months through Dec 2025 was $106.9 million (up 23.29% YoY), and the annual figure for FY2025 was $106.9 million, up 23.29%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $106.9 million at Aquestive Therapeutics, down from $110.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for AQST hit a ceiling of $110.6 million in Q3 2025 and a floor of $35.6 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $63.0 million (2023), compared with a mean of $67.0 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 77.96% in 2023 and later dropped 0.24% in 2024.
  • Aquestive Therapeutics' Shares Outstanding (Diluted Average) stood at $38.1 million in 2021, then rose by 27.99% to $48.7 million in 2022, then rose by 25.69% to $61.3 million in 2023, then skyrocketed by 41.58% to $86.7 million in 2024, then grew by 23.29% to $106.9 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $106.9 million (Q4 2025), $110.6 million (Q3 2025), and $97.4 million (Q2 2025) per Business Quant data.